You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 09/28/2016

Company Name Symbol %Change
PERFORMANT F PFMT
7.33%
COMPANIA DE BVN
4.40%
PAN AMER SIL PAAS
4.39%
GW PHARMACEU GWPH
4.19%
CLEAN ENERGY CLNE
3.91%

Analyst Blog

Sonoco (SON) Gearing Up for Growth Despite Headwinds

Posted Wed Sep 28, 05:59 pm ET

by Zacks Equity Research

On Sept 27, 2016, we issued an updated research report on Sonoco Products Co. SON, a global manufacturer of consumer and industrial packaging products.

Given a strong performance in the first half of 2016, Sonoco raised its earnings per share guidance in the range of $2.68–$2.74 from the previous range of $2.64–$2.74. The midpoint depicts an 8% year-over-year improvement in base earnings. Sonoco remains focused on further improving its cost competitiveness by optimizing its supply chain, enhancing productivity along with streamlining corporate and business unit structures.

For the third quarter, the company expects earnings per share in the range of 65 to 70 cents. Compared to the year-ago quarter’s earnings of 65 per share, this reflects flat to year-over-year growth of 8%.

Sonoco meanwhile remains committed to its ‘Grow and Optimize’ strategy, which is focused on targeted growth of its Consumer Packaging and Protective Solutions businesses as well as optimization of its Industrial-focused businesses. In line with this, Sonoco Products’ unit Sonoco ThermoSafe has acquired London-based Laminar Medica from Clinimed (Holdings) Limited.

Laminar Medica specializes in the design and manufacture of temperature controlled packaging for the global healthcare industry. Along with expanding Sonoco ThermoSafe’s global presence overall, the acquisition will particularly expand its footprint in the European Temperature-Controlled packaging market.

Earlier this month, Sonoco ThermoSafe acquired the PharmaPort 360 assets, licenses, trademarks and manufacturing rights from AAR. This buyout will help Sonoco to enter the active temperature-controlled cargo containers market. Both these acquisitions are in sync with its strategy to provide the best temperature-controlled shipping solutions to meet customers’ critical needs to ship high-value pharmaceuticals and biologics worldwide.

Recently, Sonoco Products declared that it will hike the price for all paperboard tubes and cores by 6–10% owing to the continuous rise in raw material costs. The price increase will be effective on shipments in the U.S. and Canada, beginning Oct 24, 2016. The price rise is in response to the recent increase in costs for uncoated recycled paperboard, combined with price escalations in energy, labor and other input costs. This move will help it to continue providing high-quality, value-adding products to customers.

The company will also launch several innovative products in 2016. Sonoco has capital growth projects in the pipeline through 2017 that will help expand its global production capability in composite cans, flexible packaging and rigid plastic containers.

On the flipside, Sonoco will continue to struggle with tough market conditions hurting its corrugating medium operation. Further, a strong dollar will continue to affect exports. Some of its consumer-product customers seem to be struggling to grow packaged food volumes in certain served markets.

Additionally, the Weidenhammer acquisition has increased Sonoco’s exposure to Europe. The macroeconomic weakness in the region and impact of unfavorable foreign currency translation will have a negative effect on Sonoco’s results in the near term.

At present, Sonoco carries a Zacks Rank #3 (Hold).

Stocks to Consider
 
Some other stocks worth considering in the same industry include Berry Plastics Group, Inc. BERY, Packaging Corporation of America PKG and UFP Technologies, Inc. UFPT. All of these stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, Zacks Consensus Estimate for Berry Plastics has gone up 13%. Its share price has increased 26.26% year to date.

Packaging Corporation of America witnessed an upward earnings estimate revision of approximately 1% over the past 60 days. Its share price has gained 28.09% year to date.

Over the past 30 days, the Zacks Consensus Estimate for UFP Technologies has seen upward earnings estimate revision of approximately 24%. Its share price has increased 12.47% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

6 Gold Mining Stocks to Buy as Gold Dips Post Prez Debate

Posted Wed Sep 28, 05:57 pm ET

by Zacks Equity Research

Gold lost its ground on Tuesday, as both the greenback and equity markets firmed, following the first Presidential debate and stronger-than-expected economic reports. Markets viewed that Democratic candidate Hillary Clinton outshone rival Donald Trump, thus denting the safe-haven appeal of bullion and bonds. Gold snapped its six-day winning streak with spot gold down 0.7% to $1,326.91 an ounce.

Meanwhile, the U.S. consumers’ confidence unexpectedly jumped in September, to attain its highest level since the recession. The index increased to 104.1 this month from 101.8 in August, much higher than analysts’ expectation of a reading of 99. The survey is a closely followed barometer of consumer attitudes, measures confidence toward business conditions, short-term outlook, personal finances and jobs.

This upbeat number signals that American households could continue to support economic growth in the U.S. Household spending accounts for the majority of U.S. economic activity. Healthy growth in consumer outlays supported the economy’s growth at a modest pace in second-quarter 2016, despite headwinds such as reduced business investments and lower government expenditures.

Markets Jump while Safe-Haven Metals Dip

Stocks are benefitting on the prospect of a Clinton presidency as investors are unsure of what a Trump presidency might mean for U.S. foreign policy, trade and the domestic economy. As of Tuesday close, the Dow Jones Industrial Average gained 133.47 points (0.74%) to close at 18,228.30 and the S&P 500 went up 13.83 points (0.64%) to 2,159.93. The tech-laden Nasdaq Composite Index closed at 5,305.71, gaining 0.92%. The dollar index, which weighs the greenback against a basket of currencies, was up 0.19% at 95.35.

It is a well known fact that there is an inverse relationship between the U.S. dollar and the price of gold. Gold prices for December delivery on the Comex division of the New York Mercantile Exchange closed 1% lower at $1,330.40 a troy ounce yesterday. Among other precious metals, silver fell 2.2% to $19.165 an ounce.

Gold Still Has Shine

The dip notwithstanding, prices of the yellow metal are up roughly 23% year to date. Gold has been enjoying a solid run in 2016 after three lackluster years. The Brexit-induced chaos in the global markets has spurred investors’ demand for gold. The deferral of U.S. interest rate hikes has been another major factor that has helped gold regain its shine this year.

A low-rate environment augurs well for the yellow metal. Concerns about global economic growth, along with lingering economic and political uncertainties, are likely to act in favor of gold in the near to medium term. Further, gold prices are generally helped by retail demand in countries like India and China, with the wedding and festival seasons occurring in the second half of the year.

MINING-GOLD Industry Price Index

MINING-GOLD Industry Price Index

Another factor that will eventually be a tailwind for gold is the supply of the precious metal having already attained peak levels as per reports. Global production of gold is likely to decline by 3% in 2016, thus ending a seven-year stint of rising output. Lower mined outputs forming the gold supply could help prices move north.

Grab These Glittering Stocks

Therefore, prospects for gold miners continue to remain bright. We have, thus, highlighted a few gold stocks that are good buys right now, backed by a strong Zacks Rank and upward estimate revisions and price gains till date.

Newmont Mining Corp. NEM

Colorado-based Newmont is engaged in the exploration and production of gold, and the acquisition and development of gold properties worldwide. The company carries a Zacks Rank #1 (Strong Buy) and has gained roughly 113.9% year to date. Its estimates have moved up 15% over the past 60 days. The company has a projectedearnings growth of 91.3% for the current year.

New Gold, Inc. NGD

Vancouver, Canada-based New Gold is engaged in the acquisition, exploration, development, and operation of mineral properties. It primarily explores for gold, silver and copper deposits.

New Gold has a Zacks Rank #1 and has racked up a roughly 94.83% gain so far this year. The company has expected earnings growth of around 491.7% for the current year. The Zacks Consensus Estimate for 2016 has moved up 60% over the last 30 days.

AngloGold Ashanti Ltd. AU

Headquartered in Johannesburg, South Africa, AngloGold Ashanti operates as a gold mining and exploration company. AngloGold Ashanti – which sports a Zacks Rank #2 (Buy) – has gained roughly 127.75% year to date.  You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for 2016 has moved up around 19% over the last 30 days. The stock has an impressive expected earnings growth of 440% for the current year.

IAMGOLD Corp. IAG

Toronto-based IAMGOLD is engaged in the exploration, development and operation of gold mining properties and also explores for copper and silver. IAMGOLD holds a Zacks Rank #2 and has gained roughly 188.73% year to date. The Zacks Consensus Estimate for 2016 has gone up over the past 60 days to 5 cents, an improvement from the loss of 43 cents per share in the prior year.

Gold Fields Ltd. GFI

Based in Sandton, South Africa, Gold Fields is an unhedged, globally diversified producer of gold with eight operating mines in Australia, Ghana, Peru and South Africa. This Zacks Rank #2 stock has gained roughly 76.89% year to date. The Zacks Consensus Estimate for 2016 has moved up around 14% over the last 30 days. The stock has an impressive expected earnings growth of 600% for the current year.

Acacia Mining plc ABGLF

Acacia Mining plc, together with its subsidiaries, mines, processes, and sells gold in Africa. The company also produces co-products, such as copper and silver.

The stock, which carries a Zacks Rank #2, has surged 133.96% year to date. For 2016, the Zacks Consensus Estimate is 32 cents, a huge improvement from 2 cents per share in the prior year. Estimates have moved north 23% over the past 60 days.

Now See Our Private Investment Ideas

While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>

Andersons (ANDE) to Gain from Favorable Outlook on Crops

Posted Wed Sep 28, 05:55 pm ET

by Zacks Equity Research

On Sep 27, we issued an updated research report on The Andersons, Inc. ANDE. The company stands to benefit from rising estimates for preharvest inventory levels, combined with a quality harvest. Additionally, it remains optimistic on back of a strong outlook on wheat, corn and soybean crops.

Notably, corn and soybean crop conditions are favorable in the U.S., with some spots experiencing higher than normal temperatures. Although a few localized spots in markets had lower precipitation, the crop as a whole is in a much better condition than it was last year in the Eastern Corn Belt. Additionally, rising estimates for preharvest inventory levels, combined with a quality harvest, will create income opportunities for the group late this year and into 2017.

In the plant nutrient space, Andersons remains focused on leveraging its distribution base and pursuing an increased mix of specialty product sales that support customers with solutions for precision agriculture. These products facilitate the company’s customers' yields and are a more sustainable agronomic solution.

Regarding productivity initiatives, Andersons has garnered a good momentum. Run rate costs are being reduced considerably through synergies happening primarily out of its grain and plant nutrient groups. Grain is reaping benefits from the new IT infrastructure as well as having addressed other opportunities to streamline the organization.

Moreover, Andersons anticipates results in the second half of the year to improve significantly from the first half and believes that it will post earnings per share above the current consensus level of 81 cents per share for the full year 2016. The company also remains confident that it will deliver over $10 million in run rate cost reductions by the end of 2017.

Andersons currently carries a Zacks Rank #2 (Buy).

Other Stocks to Consider

Some other favorably placed stocks worth considering in the same sector are Newmont Mining Corp. NEM, Green Plains Inc. GPRE and NL Industries Inc. NL.

Newmont Mining has seen upward estimate revisions over the past 60 days. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Green Plains, also a Zacks Rank #1 stock, has witnessed upward estimate revisions over the past 60 days.

NL Industries, which carries a Zacks Rank #1, has seen solid estimate revisions over the last 60 days.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Diageo & Amazon Collaborate to Develop Digital Mentor App

Posted Wed Sep 28, 05:52 pm ET

by Zacks Equity Research

Going Digital is the new buzzword as more and more consumers are resorting to online shopping and digital experience for the convenience and cost effectiveness it offers. The spirit industry is no exception to this prevailing trend. In a bid to offer an innovative digital experience, the leading spirits distiller Diageo plc. DEO and the online giant Amazon.com Inc. AMZN have collaborated to develop a whisky education app – Johnnie Walker Skill. The app like a mentorship program offers consumers the chance to experience the full Johnnie Walker portfolio and learn about the brand's rich history.

This digital mentorship program, Johnnie Walker Skill can be downloaded via the Amazon Alexa app and it will be guiding visitors through personalized tastings. The program recommends blends across the portfolio, provides practical whisky tips and recommends unique cocktail recipes.

The app, also helps the participants shop for the liquor of their choice. Moreover, it  offers customers the facility of purchasing Johnnie Walker for gifts, hosting at home tasting or enjoying some world class cocktails through the app.

Diageo is greatly focused on product innovation in the growing spirits and wine market. Further, the spirits and wine market is benefiting from favorable demographic trends. The baby-boomer generation is reaching its peak spirits and wine consuming age as they reach their 50s and 60s both in Europe and US.

Additionally, younger generations are consuming more spirits. The company is well poised to capture the growing market of spirits and is innovating newer varieties of spirits to attract the growing consumer base.

Diageo currently carries a Zacks Rank #3 (Hold).

Other Stock Picks

Some better-ranked stocks in the industry include Constellation Brands Inc. STZ which carries a Zacks Rank #2 (Buy) and its earnings are expected to grow by 17.7% in the long term. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Craft Brew Alliance Inc. BREW also carries a Zacks Rank #2 and has an expected long-term earnings growth rate of 25% in the next 3-5 years.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo

Posted Wed Sep 28, 05:51 pm ET

by Zacks Equity Research

Bristol-Myers Squibb Company BMY announced a clinical collaboration agreement with Nektar Therapeutics NKTR under which Bristol-Myers’ Opdivo will be evaluated in combination with Nektar’s NKTR-214 across five tumor types and seven potential indications.

The collaboration will include phase I/II studies to assess the Opdivo/NKTR-214 combination to demonstrate improved and sustained efficacy and tolerability above the current standard of care in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients. Initial dose-escalation study on the combination is in progress.

Both companies will share costs of the combination studies equally, while Nektar will retain global commercial rights to NKTR-214.

Opdivo is a PD-1 immune checkpoint inhibitor while NKTR-214 is a CD122-biased agonist. The two different and complementary mechanisms, which comprise the combination regimen, could provide new treatment options for cancer patients.

BRISTOL-MYERS Price

We are positive on this deal. Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with their cancer treatments. This July, Bristol-Myers signed up with AbbVie Inc. ABBV to study Opdivo in combination with AbbVie's Rova-T, for the treatment of relapsed extensive-stage small cell lung cancer.

We note that Opdivo generated worldwide revenues of $1.5 billion in the first half of 2016. Label expansion into additional indications would increase the commercial potential of the drug significantly.

With this deal, Nektar is also gaining a strong partner in the form of Bristol-Myers, a company with expertise in the field of immuno-oncology. Further, Nektar could expedite the development of NKTR-214, which is currently in a phase I/II study, in patients with solid tumors.

While Bristol-Myers is a Zacks Rank #3 (Hold) stock, Nektar carries a Zacks Rank #4 (Sell).

A Stock to Consider

A better-ranked stock in the health care sector is Anika Therapeutics Inc. ANIK, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

For 2016, Anika witnessed a 12.6% increase in its earnings estimates over the past 60 days. It has recorded an average positive earnings surprise of 42.19% over the last four trailing quarters. The company’s shares have jumped 22.1% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

MKS Instruments (MKSI) Down to Hold on Macro Headwinds

Posted Wed Sep 28, 05:46 pm ET

by Zacks Equity Research

On Sep 27, 2016, Zacks Investment Research downgraded MKS Instruments, Inc. MKSI to a Zacks Rank #3 (Hold) from a Zacks Rank #1 (Strong Buy). Going by the Zacks model, companies carrying a Zacks Rank #3 have chances of performing in line with the broader market over the next quarters.

Why the Downgrade?

MKS Instruments has been facing a number of headwinds in the international business forum. Appreciation of U.S. currency is weighing over the company’s international revenues and margins. This is because a stronger U.S. dollar raises the competitive power of the smaller rivals operating in low-cost nations.

Moreover, lackluster performance of booming economies such as Brazil, China and Russia has also been hurting the company’s foreign sales. We even believe that rise in political uncertainty due to the Brexit referendum has increased revenue and margin loss risks for MKS Instruments.  

Also, severe threats of business rivalry within the global technology industry might lower the market share of the company in the near term. MKS Instruments incurs heavy innovation investments for boosting its competency within the industry. However, such expenses might turn unproductive, if the newly invented technology becomes obsolete.

We believe that the company can partially offset the impact of the above mentioned headwinds by generating higher sales from the semiconductor and other advanced markets. Also, the latest Newport Corporation buyout in Apr 2016 is likely to fortify the company’s presence in the Life Sciences, Semiconductor, Research and Industrial markets. This considerably expands its addressable market.

The deal is also expected to provide significant cost synergies to the company in the upcoming 18-36 months. MKS Instruments’ Combined Targeted Operating Model is also projected to drive the company’s near-term growth..

Over the last 60 days, the Zacks Consensus Estimate for this Zacks Rank #3 stock remained unchanged for 2016 and 2017.

MKS INSTRUMENTS Price and Consensus

 

MKS INSTRUMENTS Price and Consensus | MKS INSTRUMENTS Quote

Stocks to Consider

Some better-ranked stocks within the industry that warrant a look are listed below:

Advanced Energy Industries, Inc. AEIS currently sports a Zacks Rank #1 (Strong Buy). The company has a positive average earnings surprise of 12.28% over the last four trailing quarters. You can see the complete list of today’s Zacks #1 Rank stocks here.

Intevac Inc. IVAC and Nikon Corp. NINOY carry a Zacks Rank #2 (Buy).

While Intevac generated a positive average earnings surprise of 30% over the last four trailing quarters, Nikon reported a positive average earnings surprise of 48.61% in the trailing four quarters.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Legg Mason (LM) Well Poised for Growth: Time to Hold?

Posted Wed Sep 28, 05:44 pm ET

by Zacks Equity Research

On Sep 27, 2016, we issued an updated research report on Legg Mason, Inc. LM.  The company’s top-line growth, supported by its strategic acquisitions, seems encouraging. However, the absence of improvement in investment management performance poses concern.

Legg Mason’s continuous acquisitions over the last few years, driven by a strong liquidity position have helped the company diversify its product offerings, expand its market share globally and boost its AUM growth prospects. In line with its long-term strategy of providing investors with choices “across investment capability, product and vehicle, and distribution,” the company acquired a majority stake in Financial Guard LLC, in Aug, 2016.

Moreover, the company’s cost saving measures should aid in bottom-line growth. Further, for fiscal second-quarter 2017, compensation and benefits ratio is expected to decline to the range of 52% to 54%, from 55% recorded in the fiscal first quarter. For fiscal 2017, comp ratio is expected to decrease into the range of 51% to 53%.

However, Legg Mason experienced equity outflows over the last several years with the trend continuing in fiscal first-quarter 2017 as well. In the absence of improvement in investment management performance, the company might suffer from continuous equity AUM outflows, thereby posing a threat to achieving steady overall net inflows

Further, regulatory headwinds and a low interest rate environment may affect its money market fund business, thereby impacting profitability.

Shares of Legg Mason have gained approximately 18.9% in the past three months.

Over the past 30 days, the Zacks Consensus Estimate has been revised upward by nearly 1% to $2.24 per share for fiscal year 2017.

Currently, Legg Mason carries a Zacks Rank #3 (Hold).

Other stocks to consider

Some better-ranked stocks in the finance space include Apollo Global Management, LLC APO, Virtus Investment Partners, Inc. VRTS and BlackRock, Inc. BLK.

Apollo Global witnessed a significant upward earnings estimate revision over the past 60 days. Its share price has risen 10.4% in the past six months. It currently carries a Zacks Rank #1 (Strong Buy).

Virtus Partners currently carries a Zacks Rank #1. Over the past 60 days, its Zacks Consensus Estimate has been revised 2.3% upward. Its share price has increased 27.7% in the past six months. You can see the complete list of today’s Zacks #1 Rank stocks here.

BlackRock carries a Zacks Rank #2 (Buy). It has witnessed an upward earnings estimate revision of 0.3% over the past 60 days, while its share price is up 8.86% in the past six months.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>.

Summit (SMMT): Rare Pediatric Disease Status for DMD Drug

Posted Wed Sep 28, 05:41 pm ET

by Zacks Equity Research

Summit Therapeutics plc SMMT announced that it has received Rare Pediatric Disease designation from the FDA for one of its pipeline candidates, ezutromid (utrophin modulator), for the treatment of Duchenne muscular dystrophy (DMD).

A rare pediatric disease is one that affects less than 200,000 individuals in the U.S. from birth up to 18 years of age. We note that the FDA’s rare pediatric disease priority review voucher is received upon approval of a rare pediatric disease product and can be used to obtain priority review for a subsequent marketing application for a different product. Moreover, the voucher might be sold or transferred without limitation.

The rare pediatric priority review voucher program is set to expire on Oct 1, 2016, even though the U.S. Congress is currently considering legislation to extend the program. If the program is not renewed, the FDA will no longer award pediatric vouchers to otherwise eligible sponsors.

SUMMIT THERAPTC Price

Ezutromid Receives Fast Track Status in the U.S.

Early this week, Summit also announced that it has gained Fast Track designation from the FDA for ezutromid for the treatment of DMD.

We note that the FDA grants Fast Track status to facilitate the development and speed up the review process for candidates that are being developed for the treatment of serious conditions with an unmet medical need. Fast Track status will allow Summit to interact with the FDA more frequently throughout the development. The company can also make a rolling submission of its new drug application for the candidate, which will be considered for accelerated approval and priority review.

Ezutromid is currently being evaluated for the treatment of DMD in a phase II study – PhaseOut DMD – with 24-week biopsy data from initial group of patients anticipated in the second quarter/third quarter of fiscal 2017.

We note that the candidate also enjoys Orphan Drug status for DMD in both the U.S and the EU, which will make it eligible for additional regulatory support and market exclusivity upon approval.

We remind investors that last week Sarepta Therapeutics, Inc. SRPT received accelerated approval for its DMD drug, Exondys 51, in the U.S. FDA approval makes Exondys 51 the first DMD treatment to gain approval in the U.S.

Apart from ezutromid, Summit also has ridinilazole in its pipeline. The candidate is in phase II development for the treatment of Clostridium difficile infection.

Summit currently carries a Zacks Rank #2 (Buy).

Stocks to Consider

A couple of favorably placed stocks in the health care sector are Anika Therapeutics Inc. ANIK and VIVUS Inc. VVUS. Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

For 2016, Anika witnessed a 12.6% increase in its earnings estimates over the past 60 days. It has recorded an average positive earnings surprise of 42.19% over the last four trailing quarters. The company’s shares have jumped 22.1% year to date.

VIVUS has recorded an average positive surprise of 39.88% over the last four trailing quarters. Share price of the company has surged 12.1% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Jacobs (JEC) Wins Security Contract from Woodside Energy

Posted Wed Sep 28, 05:39 pm ET

by Zacks Equity Research

Jacobs Engineering Group Inc. JEC recently secured a new security consulting service contract from the premium Australian oil & gas company, Woodside Energy Ltd., for an undisclosed sum. The deal further reinforces Jacobs’ organic growth strategy.

As per the newly received contract, Jacobs would be providing appropriate security consulting services in Woodside’s headquarters in the Capital Square progress in Perth, Western Australia. Jacobs would deliver highly connected security services for Woodside. The security trials would be integrated and interconnected across all the buildings of Woodside in the Capital Square zone. The project would be commanded by Jacob’s Perth security consulting workforce.

The security related elements of the project are anticipated to be accomplished by early 2018.

Zacks Rank and Share Price

Jacobs currently carries a Zacks Rank #3 (Hold). The company remains on track to boost its financials via new contracts, improved backlogs, greater operational efficiency and increased innovations. However, headwinds like strong U.S. dollar, robust industry competition and dismal pricing environment in the global mining and energy market raise concerns. Share price of the company was $50.75 per share as of Sep 27, 2016.

Stocks to Consider

Some better-ranked stocks within the industry are listed below:

Cotiviti Holdings, Inc. COTV presently sports a Zacks Rank #1 (Strong Buy). Over the last 60 days, the Zacks Consensus Estimate for the stock has been revised upward by 10.4% for 2016 and 5.8% for 2017. You can see the complete list of today’s Zacks #1 Rank stocks here.

Willdan Group, Inc. WLDN and Smiths Group plc SMGZY currently carry a Zacks Rank #2 (Buy). While the Zacks Consensus Estimate for Willdan Group has been revised upward by 14.9% for 2016 and 16.7% for 2017 over the last 60 days, it has been revised upward for Smiths Group plc by 1.9% for fiscal 2016 and 1.8% for fiscal 2017 over the same time period.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Visa and Oracle Team Up to Roll Out Advertising Solutions

Posted Wed Sep 28, 05:19 pm ET

by Zacks Equity Research

Visa Inc. V along with Oracle has introduced a new suite of products under Visa Advertising Solutions. Visa will leverage internet technologies from Oracle to deliver promotional advertisements to consumers.

The merchants will now be able to gain insights into their advertising campaigns run on mobile, display, video and social channels by digital advertising and cross-device connection data from Oracle Data Cloud with aggregated purchase data from Visa Advertising Solutions. These products inform merchants about the effectiveness of their online as well as in-store advertisements.

While Visa Advertising Solution will provide merchants information on potential customers based on their past purchases, knowledge of demographics and customer interests via Oracle Data Cloud. These information can be used for effective marketing.

Visa Advertising Solutions is a powerful new suite of products created exclusively for advertisers to effectively target digital ad spend. It is available on leading digital and social media platforms.

Visa also plans to partner with other strategic digital ad technology partners to provide additional Visa Advertising Solutions in the future.
Visa carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in this space are Wex Inc. WEX, Equifax Inc. EFX and Evertec Inc. EVTC. Each of these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Wex Inc. saw a 0.8% rise in its 2016 Zacks Consensus Estimate to $4.02 earnings per share over the past 60 days. On average, the company delivered a positive earnings surprise of 3.9% in the trailing four quarters.

Equifax Inc. saw a 2.7% rise in its 2016 Zacks Consensus Estimate to $5.30 earnings per share over the past 60 days. On average, the company delivered a positive earnings surprise of 4.4% in the last four quarters.

Evertec Inc. saw a 1.2% rise in its Zacks Consensus Estimate for 2016 to $1.66 earnings per share over the past 60 days. The company consistently surpassed expectations in the last four quarters, with an average beat of 1.22%.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Full Archive

The content contained in this weblog feature may have been abstracted from a complete Zacks Equity Research report.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.